{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-053419","form_type":"8-K","ticker":"ATEC","cik":"0001350653","company_name":"Alphatec Holdings, Inc.","filed_at":"2023-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.726583+00:00","generated_at":"2026-06-09T23:08:55.603884+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ATEC raises FY2023 revenue guidance to ~$472M after Q3 preliminary revenue of $117.7-118.5M","bullets":["Q3 total revenue $117.7-118.5M (+31-32% YoY), driven by lateral adoption momentum.","Surgical revenue $103.3-103.9M; EOS revenue $14.3-14.5M.","FY2023 revenue guidance raised to ~$472M from prior ~$462M.","Preliminary results; final Q3 earnings expected Nov 6, 2023 after market close."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-053419","json":"https://secwatch.observer/filing/0000950170-23-053419.json","markdown":"https://secwatch.observer/filing/0000950170-23-053419.md","text":"https://secwatch.observer/filing/0000950170-23-053419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1350653/000095017023053419/0000950170-23-053419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1350653/000095017023053419/atec-20231016.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T23:08:55.603884+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6bc4964a1086af812a03fc5b5ab02c4133c588d0","claim":"Alphatec Holdings, Inc. reported third quarter ended September 30, 2023 results: revenue $117.7M to $118.5M. Guidance raised.","evidence_excerpt":"Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today select preliminary financial results for the third quarter ended September 30, 2023, and updated full-year 2023 revenue guidance ahead of investor meetings scheduled during the 2023 North American Spine Society (NASS) Annual Meeting . Preliminary Third Quarter 2023 Revenue Ranges Quarter Ended September 30, 2023 Surgical Revenue $103.3M to $103.9M EOS Revenue $14.3M to $14.5M Total Revenue $117.7M to $118.5M","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1350653/000095017023053419/0000950170-23-053419-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$117.7M to $118.5M"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}